Oramed Pharmaceuticals (ORMP) Assets Average (2011 - 2026)
Oramed Pharmaceuticals' (ORMP) quarterly Assets Average came in at $249.9 million in Q1 2026, up 65.02% YoY from $151.4 million in Q1 2025, and up 10.71% on a QoQ basis from $225.7 million in Q4 2025.
Oramed Pharmaceuticals (ORMP) Assets Average (2011 - 2026) Analysis & Trends
Oramed Pharmaceuticals (ORMP) has 16 years of Assets Average data on file, last reported at $249.9 million in Q1 2026.
- Quarterly Assets Average rose 65.02% year-over-year to $249.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $249.9 million (up 65.02% YoY) and the FY2025 annual result came in at $193.1 million, up 2.74% from the prior year.
- Assets Average climbed to $249.9 million in Q1 2026, from $225.7 million in the prior quarter.
- In the past five years, Assets Average ranged from a high of $249.9 million in Q1 2026 to a low of $151.4 million in Q1 2025.
- A 5-year average of $183.7 million and a median of $174.7 million in 2024 frame the typical range for Assets Average.
- Annual changes were most pronounced in 2024 — Assets Average retreated 29.04% — and 2026, when it surged 65.02%.
- Tracing ORMP's Assets Average over 5 years: stood at $163.0 million in 2022, then jumped by 38.45% to $225.7 million in 2023, then dropped by 29.04% to $160.2 million in 2024, then surged by 40.89% to $225.7 million in 2025, then gained by 10.71% to $249.9 million in 2026.
- The last three Assets Average figures came in at $249.9 million (Q1 2026), $225.7 million (Q4 2025), and $191.1 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 26.95 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 41.30 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 11.22 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 8.86 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 5.34 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 2.09 Bn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 19.82 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 25.27 Bn |
| 10 | Oramed Pharmaceuticals | 196.17 Mn | 196.17 Mn | - | 319.25 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 319.25 Mn |
| Mar 31, 2026 | 249.86 Mn |
| Dec 31, 2025 | 225.68 Mn |
| Sep 30, 2025 | 191.09 Mn |
| Jun 30, 2025 | 154.61 Mn |
| Mar 31, 2025 | 151.41 Mn |
| Dec 31, 2024 | 160.18 Mn |
| Sep 30, 2024 | 174.65 Mn |
| Jun 30, 2024 | 193.94 Mn |
| Mar 31, 2024 | 212.10 Mn |
| Dec 31, 2023 | 225.72 Mn |
| Sep 30, 2023 | 193.60 Mn |
| Jun 30, 2023 | 158.05 Mn |
| Mar 31, 2023 | 160.71 Mn |
| Dec 31, 2022 | 163.04 Mn |
| Sep 30, 2022 | 163.36 Mn |
| Jun 30, 2022 | 167.26 Mn |
| Mar 31, 2022 | 177.34 Mn |
| Nov 30, 2021 | 155.22 Mn |
| Aug 31, 2021 | 104.25 Mn |